ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety. Read why I am bullish about ...
ImmunityBio Inc. IBRX shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform. • ImmunityBio shares are powering higher. Why is ...
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results